Albupharm Heidelberg Gmbh & Co. Kg

Deutsches Krebsforschungszentrum Stiftund Des Offentlichen Rechts

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen

Hannsjörg Sinn

Wolfgang Maier-Borst

Gerd Stehle

Hans-Hermann Schrenk

Michael Kaus

Marcel Mülbaier

The present invention is directed to a Gyrase inhibitor-protein conjugate; in particular a Gyrase inhibitor-albumin conjugate. The present invention further provides methods of the treatment of inflammatory conditions and tumors. Methods of making and producing a Gyrase inhibitor-protein conjugate are also disclosed.

Method for producing albumin conjugates containing gyrase inhibitors

A method for modulating a transplantation-associated immune response in a subject is disclosed. The method comprises administering to the subject an effective amount of a conjugate comprising a carboxyl group-containing organic compound and albumin, wherein the carboxyl group-containing organic compound is a cytostatic or an immunosuppressant. A method for preparing the conjugate is also disclosed. The method includes activating the carboxyl group-containing organic compound with 1-ethyl-3-(3-dimethylaminopropyl) carbonyldiimide in an organic solvent, and reacting activated carboxyl group-containing organic compound with albumin, wherein the carboxyl group-containing organic compound is a cytostatic or an immunosuppressant.

Production and use of the methotrexate-albumin conjugate as an immunosuppressive agent in GVHD

Conjugate of an active agent, a polyether and possibly a native protein

Method for producing chlorins and bacteriochlorins containing polyether

Growing community of inventors

Wiesloch, Germany

Hannsjörg Sinn